Pharma Focus Asia

Novo Nordisk invests DKK 2.1 billion in new insulin filling facility in Hillerød, Denmark


Novo Nordisk announced plans to invest DKK 2.1 billion in a new 10,300 m2 facility in Hillerød, Denmark.


The facility will produce medicines for the treatment of diabetes and obesity. The facility is expected to be operational in 2019 and will create 450 new production and engineering jobs in Hillerød, where Novo Nordisk already employs 1,900 people.

Incorporating the latest state-of-the-art insulin production technology, the new insulin filling facility will ensure production capacity for existing and future products within diabetes.

The investment in Hillerød underscores our long-term ambition to create and maintain jobs in Denmark. This year alone we have created 1,000 new jobs in Denmark, of which 500 are in production, primarily in Kalundborg and Hillerød, said Henrik Wulff, executive vice president and head of Product Supply, Novo Nordisk.


NameNovo Nordisk
LocationHillerød, Denmark
TypeInsulin Filling Facility
Estimated CostDKK 2.1 Billion
Operational By2019
Jobs450 Jobs
Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024Equinix accelerated medical research...CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024
Searching for an end-to-end patient tech solution?